DataM Intelligence Analyzes Myelofibrosis Market Growth to 2035
A new industry report forecasts the global myelofibrosis market to reach $3.48 billion by 2035, driven by a shift toward mechanism-diverse combination therapies.
The myelofibrosis treatment landscape is moving away from a single JAK-inhibitor paradigm toward specialized, phenotype-directed combinations, according to market research from DataM Intelligence. While incumbents like Incyte, GSK, Sobi, and Bristol Myers Squibb currently dominate the market with FDA-approved therapies, the arrival of new clinical data is intensifying competition.
The global market, valued at $1.7 billion in 2025, is projected to grow at a 7.6% CAGR over the next decade. Analysts indicate that future commercial success will depend less on spleen-volume reduction and more on a therapy’s ability to manage anemia, transfusion burden, and long-term hematologic safety in patients who have failed previous JAK-inhibitor treatments.
Pipeline diversity remains high as pharmaceutical companies test new mechanisms, including XPO1 inhibition, telomerase inhibition, and BET inhibition. Notable programs in late-stage development include combination therapies such as selinexor plus ruxolitinib and navtemadlin, reflecting a broader effort to achieve deeper control of the malignant clone rather than mere symptom management.